| Ytd | 3.81% | |
| 1y | -50.23% |
| Open | 1.12 | Prev Close | 1.09 | Low | 1.07 | High | 1.13 | Mkt Cap | 12.66M |
| Vol | 93.42K | Avg Vol | 608.51K | EPS | -1.38 | P/E | -0.79 | Forward P/E | 0.07 |
| Beta | 1.47 | Short Ratio | 0.50 | Inst. Own | 3.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.04 | 200-d Avg | 1.17 | 1yr Est | 36.00 |
PHIO News
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASD
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale A
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile
Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfil
Brings extensive experience in patient care, dermatologic research and commercialization King of Pru
The company has received multiple favorable patent actions encompassing three notices of allowance
Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds
Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manu
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:
Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendFeatur
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDA
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas King of Prussi
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunot